Opinion|Videos|October 7, 2024
Current Treatment Options for Dravet Syndrome
Author(s)M. Scott Perry, MD
Key Takeaways
- The primary treatment goal for Dravet syndrome is reducing seizure frequency and severity while improving quality of life and minimizing side effects.
- Initial treatments for Dravet syndrome include valproate and clobazam, which are effective in managing seizures.
The panelist discusses how the goal of Dravet syndrome treatment is to reduce seizure frequency and severity, typically starting with initial treatments like valproate and clobazam and potentially escalating to combination therapies including options such as cannabidiol, with the overall aim of improving patients’ quality of life and developmental outcomes
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the goal of treatment for Dravet syndrome?
- Please describe the recommended initial treatments for Dravet syndrome.
- Valproate
- Clobazam
- Please describe the recommended initial treatments for Dravet syndrome.
- Please describe treatment options that are available as escalation therapy in combination with initial treatments for Dravet syndrome.
- Stiripentol
- Cannabidiol
- Fenfluramine
Advertisement
Related to this article
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
Xenon Pharmaceuticals submitted an FDA new drug application for azetukalner, a KV7 potassium channel opener, as adjunctive therapy for focal seizures in epilepsy.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
Marketed as Fayuvi, the 1-time AAV9 gene therapy showed sustained cerebrospinal fluid heparan sulfate drops and developmental gains among pediatric patients with mucopolysaccharidosis type IIIA in prior studies.
Amy Waldman, MD, Medical Director of the Leukodystrophy Center at Children's Hospital of Philadelphia, discusses zilganersen's mechanism, safety profile, clinical considerations, and what the first-ever approval for Alexander disease means for the broader leukodystrophy field.
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
2
Ulefnersen Meets Primary End Point in Phase 3 FUSION Trial for FUS-ALS
3
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
4
Closing the Gaps in Cluster Headache Care: Jennifer Fokas, MD; Minali Nigam, MD
5